As a provider of bespoke services for the discovery of dynamic biomarkers, Sapient leverages its high throughput, untargeted metabolomics approaches to probe deeper into the human metabolome at a rate is unmatched for discovery. Our mass spectrometry-based methods lead the metabolomics services market in speed and scalability, enabling us to rapidly uncover both known and unknown biomarkers that associate with early disease, disease progression, and drug response.
By pairing nontargeted data generation with advanced metabolomics data analysis, including statistical and pathway analysis, we help identify robust biomarkers to elucidate disease biology, enrich clinical trials, and align patients, disease, and precision therapies. How does it work?
Learn more about why Sapient is the choice partner for metabolomics biomarker discovery, and how we can work together to advance your drug programs at any phase. Use the sidebar to download our fact sheet or request services directly.
"(Required)" indicates required fields
You can schedule a meeting to discuss details and turnaround time using the link below.